Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$65.69 USD

65.69
12,418,430

-2.33 (-3.43%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $65.65 -0.04 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

5 Top-Performing ETFs of Last Week

Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.

Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Sanghamitra Saha headshot

4 Sectors to Prosper in Thanksgiving Week

Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.

Mark Vickery headshot

Markets Up on Sunny Holiday Outlook

The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.

Mark Vickery headshot

AstraZeneca-Oxford Vaccine at 70% Efficacy

One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.

Stock Market News for Nov 20, 2020

U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.

EOG Resources (EOG) Up 32.8% MTD: What's Behind the Rally?

Improving oil prices on positive coronavirus vaccine results aid EOG Resources (EOG).

5 Top Stocks to Buy Amid Potential Economic Recovery

With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).

Sweta Killa headshot

Small Caps at the Forefront of Market Rally: 5 ETF Winners

While the rally has been broad-based across all the market caps, small-caps stocks, as indicated by the Russell 2000 Index, has been outperforming and is hitting new all-time highs.

Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.

Ritujay Ghosh headshot

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

Nilanjan Choudhury headshot

U.S. Crude Hits its Highest Price in 2 Months: Here's Why

Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).

Kevin Cook headshot

Bull Market to Surge on Vaccine Snapback

How 5% GDP and 25% EPS growth could fuel a run to S&P 4,500 in 2021.

Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS

Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.

Sweta Killa headshot

Bet on Quality ETFs as Vaccine Hope & Coronavirus Cases Rise

Quality ETFs could enjoy smooth trading and generate market-beating returns in the current market environment.

Maharathi Basu headshot

Airline Stock Roundup: LUV's Bleak Update, Azul's Q3 Loss, ALGT's Traffic & More

Southwest Airlines (LUV) expects operating revenues to be down 60-65% in both November and December. Meanwhile, Azul (AZUL) performs badly in Q3 due to coronavirus-led revenue weakness.

Sweta Killa headshot

Why Cyclical Sector ETFs Are Roaring to All-Time Highs

Vaccine optimism has spurred buying in cyclical sectors, which are tied to economic activities.

Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU

Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.

Sweta Killa headshot

Small-Cap ETF (VTWO) Hits New 52-Week High

This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?

Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Nilanjan Banerjee headshot

Schlumberger (SLB) Up 11.3% in a Day: What's Behind the Rally?

Improving fuel demand on positive coronavirus vaccine results aids Schlumberger (SLB).

Sweta Killa headshot

Dow ETF Hits New Highs on Vaccine Optimism: 5 Best Stocks

The Dow Jones hit all-time highs since February, marking its fastest bear market recovery in 30 years.

Disappointing Retail Sales Data for October

Disappointing Retail Sales Data for October.

Maharathi Basu headshot

Why Airline Space is Upbeat Despite Spike in US Coronavirus Cases

The positive update on Moderna's (MRNA) coronavirus vaccine candidate drives airline stocks like Delta (DAL), American Airlines (AAL), United Airlines (UAL) and Southwest Airlines (LUV) higher on Nov 16..

Mark Vickery headshot

Economic Metrics Slimmer, Walmart (WMT) Beats Estimates

All of today's reads are for the month of October: Retail Sales, Import and Export Price Indexes and Industrial Production and Capacity Utilization.